Theranostics · 2026
c-Met-targeted NIR-II imaging for precision management of oral squamous cell carcinoma and premalignant lesions.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xia Zhipeng, Ji Aiyan, Ma Qifan, Li Yonghao, Lou Hongyue, Qian Kun, Tian Jie, Yuan Ying, Cheng Zhen, Tao Xiaofeng
Аннотация
BACKGROUND: Poor outcomes in oral squamous cell carcinoma (OSCC) are closely linked to delayed diagnosis, positive surgical margins and occult lymph node metastasis. A unified strategy for premalignant lesion screening, primary tumor delineation and metastatic lymph node detection remains lacking.
METHODS: We evaluated c-Met expression in human oral lesions, OSCC tissues and metastatic lymph nodes to establish its suitability as an imaging target. On this basis, we developed IR788-Crizotinib, a c-Met-targeted near-infrared window-II (NIR-II) fluorescent probe, and evaluated its imaging performance in subcutaneous xenograft, 4-NQO-induced oral lesion, orthotopic tongue OSCC and lymph node metastasis mouse models.
RESULTS: c-Met expression increased progressively during oral lesion progression and remained high in metastatic tumor deposits within lymph nodes. IR788-Crizotinib identified high-risk lesions with 100% sensitivity and 96.77% accuracy, including severe dysplasia lesions as small as 300 μm and microinvasive OSCC lesions as small as 286 μm. In fluorescence-guided surgery models, the probe identified multifocal tumors and detected residual foci as small as 1 mm. In cervical lymph nodes, it detected micro-metastatic foci as small as 342 μm, with 100% sensitivity.
CONCLUSIONS: c-Met-targeted NIR-II imaging provides an integrated visualization strategy for premalignant lesion screening, primary tumor delineation and metastatic lymph node detection in OSCC, with translational potential for precision management of oral cancer.
METHODS: We evaluated c-Met expression in human oral lesions, OSCC tissues and metastatic lymph nodes to establish its suitability as an imaging target. On this basis, we developed IR788-Crizotinib, a c-Met-targeted near-infrared window-II (NIR-II) fluorescent probe, and evaluated its imaging performance in subcutaneous xenograft, 4-NQO-induced oral lesion, orthotopic tongue OSCC and lymph node metastasis mouse models.
RESULTS: c-Met expression increased progressively during oral lesion progression and remained high in metastatic tumor deposits within lymph nodes. IR788-Crizotinib identified high-risk lesions with 100% sensitivity and 96.77% accuracy, including severe dysplasia lesions as small as 300 μm and microinvasive OSCC lesions as small as 286 μm. In fluorescence-guided surgery models, the probe identified multifocal tumors and detected residual foci as small as 1 mm. In cervical lymph nodes, it detected micro-metastatic foci as small as 342 μm, with 100% sensitivity.
CONCLUSIONS: c-Met-targeted NIR-II imaging provides an integrated visualization strategy for premalignant lesion screening, primary tumor delineation and metastatic lymph node detection in OSCC, with translational potential for precision management of oral cancer.